Grapefruit

No measurable IgG antibodies to grapefruit were identified. This suggests minimal immune reactivity. Grapefruit is unlikely to be contributing to delayed immune-related symptoms for most individuals.

A very low result indicates trace immune recognition and is generally considered clinically insignificant. Most individuals with very low grapefruit IgG tolerate grapefruit without issue.

A low result reflects mild immune exposure and is common in those who occasionally consume citrus fruits. If symptoms are suspected, evaluating portion size or acidity tolerance may be helpful before full elimination.

A moderate result indicates a noticeable immune response to grapefruit proteins. In symptomatic individuals, this may correlate with delayed digestive discomfort, fatigue, headaches, skin changes, sinus symptoms, or inflammatory-type complaints. A structured elimination period followed by careful reintroduction can help determine whether grapefruit is contributing to symptoms. During evaluation, it is important to distinguish immune-related reactions from acid sensitivity or medication interactions.

A high result reflects strong IgG reactivity to grapefruit. In individuals with consistent delayed symptoms after consumption, this may suggest grapefruit is contributing to ongoing digestive or inflammatory symptoms. Temporary elimination with later reintroduction is often considered. High IgG does not indicate a true citrus allergy, but immediate reactions such as hives, swelling, vomiting, or breathing difficulty require formal allergy evaluation.

Across all result levels, grapefruit IgG findings should be interpreted in context. Because grapefruit is acidic and can interact with certain medications, evaluating overall health context alongside immune markers is essential. Structured elimination trials and careful symptom tracking remain the most reliable methods for determining clinical relevance.